iRadimed (NASDAQ:IRMD) Sees Large Volume Increase - Should You Buy?

Key Points

• iRadimed reported a Q1 beat with non‑GAAP EPS of $0.49 and ~13% revenue growth, raised FY2026 EPS guidance to $2.06–$2.21, and increased the quarterly dividend to $0.20.
• Trading volume roughly doubled to 167,495 shares while the stock traded around $83.66, and analysts remain constructive with a consensus Buy rating and an average price target near $120.
• Near‑term risks include mixed Q2 guidance (revenue guidance of $20.0–$21.0M is slightly below Street estimates) and recent insider selling (CEO sold 3,750 shares; insiders sold ~48,750 shares over the past three months).

iRadimed Corporation (NASDAQ:IRMD - Get Free Report) saw strong trading volume on Friday . 167,495 shares changed hands during trading, an increase of 100% from the previous session's volume of 83,589 shares.The stock last traded at $83.66 and had previously closed at $83.44.

Trending Headlines about iRadimed

Here are the key news stories impacting iRadimed this week:

• Positive Sentiment: Q1 beat — iRadimed reported Q1 non‑GAAP EPS of $0.49 (GAAP $0.45) and revenue up ~13% year‑over‑year; EPS topped consensus and showed margin strength, providing the primary catalyst for the move. iRadimed (IRMD) Beats Q1 Earnings and Revenue Estimates
• Positive Sentiment: FY guidance slightly raised and reaffirmed — management set FY2026 EPS guidance at $2.06–$2.21, modestly above consensus, which supports the view that growth and margins are intact for the year. IRADIMED CORPORATION Reports First Quarter 2026 Financial Results
• Positive Sentiment: Dividend raised/paid — company announced a regular quarterly cash dividend of $0.20 per share (up from $0.17), which is shareholder‑friendly and may attract income‑oriented buyers. IRADIMED CORPORATION Reports First Quarter 2026 Financial Results
• Neutral Sentiment: Q2 guidance mixed — Q2 EPS guidance of $0.44–$0.48 is around consensus but revenue guidance of $20.0–$21.0M is just below street estimates, suggesting near‑term top‑line variability to monitor. IRADIMED CORPORATION Reports First Quarter 2026 Financial Results
• Neutral Sentiment: Wall Street coverage remains constructive — several analysts maintain Buy/Strong Buy ratings and ~$120 average target, which supports upside but also sets expectations. MarketBeat iRadimed Research
• Negative Sentiment: Insider sale — CEO Roger Susi sold 3,750 shares under a pre‑arranged Rule 10b5‑1 plan; while small relative to his holdings, insider selling can be perceived negatively by some investors. Insider Selling: iRadimed CEO Sells 3,750 Shares

Analysts Set New Price Targets

A number of analysts recently commented on the company. Lake Street Capital reiterated a "buy" rating and set a $120.00 price objective on shares of iRadimed in a research report on Wednesday, February 11th. Roth Mkm reiterated a "buy" rating and set a $120.00 price objective on shares of iRadimed in a research report on Tuesday, February 10th. Finally, Freedom Capital upgraded iRadimed to a "strong-buy" rating in a research report on Thursday, April 2nd. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $120.00.

iRadimed Price Performance

The company has a market cap of $1.11 billion, a PE ratio of 49.71 and a beta of 1.11. The business has a 50-day moving average of $96.69 and a 200 day moving average of $93.87.

iRadimed (NASDAQ:IRMD - Get Free Report) last posted its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $0.54 EPS for the quarter, beating analysts' consensus estimates of $0.49 by $0.05. iRadimed had a return on equity of 23.83% and a net margin of 26.82%.The company had revenue of $22.69 million during the quarter, compared to analysts' expectations of $21.60 million. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. On average, equities analysts predict that iRadimed Corporation will post 1.94 EPS for the current fiscal year.

iRadimed Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, March 6th. Shareholders of record on Monday, February 23rd were issued a dividend of $0.20 per share. This is a boost from iRadimed's previous quarterly dividend of $0.17. This represents a $0.80 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend was Monday, February 23rd. iRadimed's dividend payout ratio is presently 45.71%.

Insider Transactions at iRadimed

In other iRadimed news, CEO Roger E. Susi sold 3,750 shares of the business's stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $89.16, for a total transaction of $334,350.00. Following the completion of the sale, the chief executive officer owned 2,198,750 shares of the company's stock, valued at approximately $196,040,550. The trade was a 0.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 48,750 shares of company stock worth $4,708,950 over the last three months. Insiders own 36.80% of the company's stock.

Institutional Trading of iRadimed

Several hedge funds have recently bought and sold shares of IRMD. CWM LLC grew its holdings in iRadimed by 62.2% during the third quarter. CWM LLC now owns 550 shares of the medical equipment provider's stock valued at $39,000 after purchasing an additional 211 shares during the period. Quarry LP bought a new stake in iRadimed during the third quarter valued at about $40,000. Farther Finance Advisors LLC grew its holdings in iRadimed by 827.1% during the fourth quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider's stock valued at $43,000 after purchasing an additional 397 shares during the period. Tower Research Capital LLC TRC boosted its stake in shares of iRadimed by 191.1% in the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider's stock worth $45,000 after acquiring an additional 495 shares during the period. Finally, State of Alaska Department of Revenue bought a new position in shares of iRadimed in the third quarter worth about $47,000. Institutional investors own 92.34% of the company's stock.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company's core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.